CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor - PubMed (original) (raw)
CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor
K L Bennett et al. J Cell Biol. 1995 Feb.
Abstract
Glycosaminoglycan-modified isoforms of CD44 have been implicated in growth factor presentation at sites of inflammation. In the present study we show that COS cell transfectants expressing CD44 isoforms containing the alternatively spliced exon V3 are modified with heparan sulfate (HS). Binding studies with three HS-binding growth factors, basic-fibroblast growth factor (b-FGF), heparin binding-epidermal growth factor (HB-EGF), and amphiregulin, showed that the HS-modified CD44 isoforms are able to bind to b-FGF and HB-EGF, but not AR. b-FGF and HB-EGF binding to HS-modified CD44 was eliminated by pretreating the protein with heparitinase or by blocking with free heparin. HS-modified CD44 immunoprecipitated from keratinocytes, which express a CD44 isoform containing V3, also bound to b-FGF. We examined whether HS-modified CD44 isoforms were expressed by activated endothelial cells where they might present HS-binding growth factors to leukocytes during an inflammatory response. PCR and antibody-binding studies showed that activated cultured endothelial cells only express the CD44H isoform which does not contain any of the variably spliced exons including V3. Immunohistological studies with antibodies directed to CD44 extracellular domains encoded by the variably spliced exons showed that vascular endothelial cells in inflamed skin tissue sections do not express CD44 spliced variants. Keratinocytes, monocytes, and dendritic cells in the same specimens were found to express variably spliced CD44. 35SO4(-2)-labeling experiments demonstrated that activated cultured endothelial cells do not express detectable levels of chondroitin sulfate or HS-modified CD44. Our results suggest that one of the functions of CD44 isoforms expressing V3 is to bind and present a subset of HS-binding proteins. Furthermore, it is probable that HS-modified CD44 is involved in the presentation of HS-binding proteins by keratinocytes in inflamed skin. However, our data suggests that CD44 is not likely to be the proteoglycan principally involved in presenting HS-binding growth factors to leukocytes on the vascular cell wall.
Similar articles
- Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.
Jackson DG, Bell JI, Dickinson R, Timans J, Shields J, Whittle N. Jackson DG, et al. J Cell Biol. 1995 Feb;128(4):673-85. doi: 10.1083/jcb.128.4.673. J Cell Biol. 1995. PMID: 7532175 Free PMC article. - Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers.
Grimme HU, Termeer CC, Bennett KL, Weiss JM, Schöpf E, Aruffo A, Simon JC. Grimme HU, et al. Br J Dermatol. 1999 Nov;141(5):824-32. doi: 10.1046/j.1365-2133.1999.03154.x. Br J Dermatol. 1999. PMID: 10583162 - CD44: structure, function, and association with the malignant process.
Naor D, Sionov RV, Ish-Shalom D. Naor D, et al. Adv Cancer Res. 1997;71:241-319. doi: 10.1016/s0065-230x(08)60101-3. Adv Cancer Res. 1997. PMID: 9111868 Review. - Schwann cell tumors express characteristic patterns of CD44 splice variants.
Sherman L, Skroch-Angel P, Moll J, Schwechheimer K, Ponta H, Herrlich P, Hofmann M. Sherman L, et al. J Neurooncol. 1995 Dec;26(3):171-84. doi: 10.1007/BF01052620. J Neurooncol. 1995. PMID: 8750183 Review.
Cited by
- Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, Ohkoshi A, Kaneko MK, Katori Y, Kato Y. Ishikawa K, et al. Int J Mol Sci. 2024 Aug 24;25(17):9190. doi: 10.3390/ijms25179190. Int J Mol Sci. 2024. PMID: 39273139 Free PMC article. - CD44 and its implication in neoplastic diseases.
Xu Y, Bai Z, Lan T, Fu C, Cheng P. Xu Y, et al. MedComm (2020). 2024 May 23;5(6):e554. doi: 10.1002/mco2.554. eCollection 2024 Jun. MedComm (2020). 2024. PMID: 38783892 Free PMC article. Review. - A Narrative Review on CD44's Role in Glioblastoma Invasion, Proliferation, and Tumor Recurrence.
Inoue A, Ohnishi T, Nishikawa M, Ohtsuka Y, Kusakabe K, Yano H, Tanaka J, Kunieda T. Inoue A, et al. Cancers (Basel). 2023 Oct 9;15(19):4898. doi: 10.3390/cancers15194898. Cancers (Basel). 2023. PMID: 37835592 Free PMC article. Review. - Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation.
Goto N, Suzuki H, Zheng L, Okano Y, Okita Y, Watanabe Y, Kato Y, Kato M. Goto N, et al. Cancer Sci. 2023 Oct;114(10):3972-3983. doi: 10.1111/cas.15934. Epub 2023 Aug 22. Cancer Sci. 2023. PMID: 37607779 Free PMC article. - Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas.
Suzuki H, Goto N, Tanaka T, Ouchida T, Kaneko MK, Kato Y. Suzuki H, et al. Antibodies (Basel). 2023 Jul 4;12(3):45. doi: 10.3390/antib12030045. Antibodies (Basel). 2023. PMID: 37489367 Free PMC article.
References
- Cell. 1991 Feb 22;64(4):841-8 - PubMed
- Science. 1991 Jun 21;252(5013):1705-8 - PubMed
- J Cell Biol. 1992 Aug;118(4):971-7 - PubMed
- J Cell Biol. 1994 Jul;126(2):391-401 - PubMed
- J Biol Chem. 1994 Jan 28;269(4):2541-9 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous